Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.57 |
| ▸ | GSK3B | P49841 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.42 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13119674 | 0.93 | CDK2 (0.58) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119551 | 0.93 | CDK2 (0.61) | CDK2GSK3BMEN1KMT2ACCNA2 | |
| SCHEMBL13119671 | 0.93 | CDK2 (0.57) | CDK2GSK3BMEN1KMT2ACCNA2 | |
| SCHEMBL13119714 | 0.92 | CDK2 (0.58) | CDK2GSK3BMEN1KMT2ACCNA2 | |
| SCHEMBL13119331 | 0.92 | CDK2 (0.60) | CDK2GSK3BMEN1KMT2ACCNA2 | |
| SCHEMBL13121757 | 0.92 | CDK2 (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119686 | 0.90 | CDK2 (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119639 | 0.90 | CDK2 (0.62) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119452 | 0.89 | CDK2 (0.63) | CDK2GSK3BMEN1KMT2ACCNA2 | |
| SCHEMBL13119684 | 0.89 | CDK2 (0.61) | CDK2GSK3BCCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |